Myosin 1C isoform A is a novel candidate diagnostic marker for prostate cancer

Abstract

Early diagnosis of prostate cancer is a challenging issue due to the lack of specific markers. Therefore, a sensitive diagnostic marker that is expressed or upregulated exclusively in prostate cancer cells would facilitate diagnostic procedures and ensure a better outcome. We evaluated the expression of myosin 1C isoform A in 5 prostate cell lines, 41 prostate cancer cases, and 11 benign hyperplasias. We analyzed the expression of 12 surface molecules on prostate cancer cells by flow cytometry and analyzed whether high or low myosin 1C isoform A expression could be attributed to a distinct phenotype of prostate cancer cells. Median myosin 1C isoform A expression in prostate cancer samples and cancer cell lines was 2 orders of magnitude higher than in benign prostate hyperplasia. Based on isoform A expression, we could also distinguish clinical stage 2 from clinical stage 3. Among cell lines, PC-3 cells with the highest myosin 1C isoform A level had diminished numbers of CD10/CD13-positive cells and increased numbers of CD29 (integrin β1), CD38, CD54 (ICAM1) positive cells. The surface phenotype of clinical samples was similar to prostate cancer cell lines with high isoform A expression and could be described as CD10-/CD13- with heterogeneous expression of other markers. Both for cell lines and cancer specimens we observed the strong correlation of high myosin 1C isoform A mRNA expression and elevated levels of CD29 and CD54, suggesting a more adhesive phenotype for cells with high isoform A expression. Compared to normal tissue, prostate cancer samples had also reduced numbers of CD24- and CD38-positive cells. Our data suggest that a high level of myosin 1C isoform A is a specific marker both for prostate cancer cells and prostate cancer cell lines. High expression of isoform A is associated with less activated (CD24/CD38 low) and more adhesive (CD29/CD54 high) surface phenotype compared to benign prostate tissue.

METTL3-mediated deficiency of lncRNA HAR1A drives non-small cell lung cancer growth and metastasis by promoting ANXA2 stabilization

“…4B ). Among them, myosin IC (MYO1C) and annexin 2 (ANXA2) were found to be the most abundant protein among all identified proteins (Table S2 ), and they have been reported to be associated with carcinogenesis [ 22 – 24 ]. The peptide mass fingerprinting of ANXA2 is displayed in Fig.…”

RAB31 in glioma‐derived endothelial cells promotes glioma cell invasion via extracellular vesicle‐mediated enrichment of MYO1C

“…MYO1C has been reported to mediate vesicular trafficking in cells; here, we focused on its role as a vesicular cargo [ 29 ]. It is also worth noting that myosin 1C isoform A is a novel candidate diagnostic marker for prostate cancer [ 30 ]. Our results demonstrated that MYO1C overexpression can promote the aggressiveness of U87MG cells, while in GSC2, it appeared to promote the cell proliferation capacity; this differential effect may be due to the difference in cellular expression levels of MYO1C protein or stem cell characteristics.…”

Parameters of Cell Death and Proliferation of Prostate Cancer Cells with Altered Expression of Myosin 1C Isoforms

“…The analysis of the expression of isoform A in prostate cancer cell lines showed that, using real-time PCR, it is possible to detect an increase in the level of mRNA expression of this isoform even in samples with a small number of cells or in samples with a large amount of the stromal component [ 12 ]. In addition, the level of expression of isoform A is significantly increased in clinical samples of prostate cancer and makes it possible to distinguish not only the tumor process from reactive benign prostatic hyperplasia but also the stages of the tumor from each other, which opens up new prospects for its use as a diagnostic and prognostic marker [ 13 ]. In this work, we hypothesized that exogenous changes in the expression level of myosin 1C may affect the balance of death parameters in prostate cancer cell lines.…”